Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

BACKGROUNDS AND AIMS: Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gigante, Elia, Hobeika, Christian, Le Bail, Brigitte, Paradis, Valérie, Tougeron, David, Lequoy, Marie, Bouattour, Mohamed, Blanc, Jean-Frederic, Ganne-Carrié, Nathalie, Tran, Henri, Hollande, Clémence, Allaire, Manon, Amaddeo, Giuliana, Regnault, Hélène, Vigneron, Paul, Ronot, Maxime, Elkrief, Laure, Verset, Gontran, Trepo, Eric, Zaanan, Aziz, Ziol, Marianne, Ningarhari, Massih, Calderaro, Julien, Edeline, Julien, Nault, Jean-Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485952/
https://www.ncbi.nlm.nih.gov/pubmed/36158591
http://dx.doi.org/10.1159/000525488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485952/
https://www.ncbi.nlm.nih.gov/pubmed/36158591
http://dx.doi.org/10.1159/000525488

Ejemplares similares